晚期乳腺癌患者血清Her-2/neu浓度与化疗疗效的关系

中国癌症防治杂志

晚期乳腺癌患者血清Her-2/neu浓度与化疗疗效的关系

宋向群;周建红;于起涛;曾爱屏;周达;何剑波;

广西医科大学附属肿瘤医院化疗二科;广西医科大学研究生学院;

收稿日期:2009-03-25 修回日期:2009-03-25 出版日期:2009-03-25 发布日期:2009-03-25

Serum concentration of Her-2/neu in patients with advanced breast cancer and its relationship with efficacy of chemotherapy

SONG Xiang-qun,ZHOU Jian-hong,YU Qitao.et al.

(The Second Department of Chemotherapy,Affiliated Tumor Hospital of Guangxi Medical University,Nanning 530021,China

Received:2009-03-25 Revised:2009-03-25 Online:2009-03-25 Published:2009-03-25

摘要/Abstract

摘要： 目的探讨晚期乳腺癌患者血清Her-2/neu浓度变化与化疗疗效的关系及临床意义。方法采用酶联免疫法(ELISA)检测66例晚期乳腺癌患者化疗前和化疗后血清Her-2/neu的浓度,并与组织Her-2/neu表达比较,分析两者的相关性和对化疗疗效、疾病进展时间(TTP)的影响。结果晚期乳腺癌患者的血清Her-2/neu浓度与肿瘤组织中Her-2/neu表达有一致性(P<0.001)。治疗前血清Her-2/neu水平与化疗疗效无关(P>0.05)。化疗有效的患者血清Her-2/neu浓度从治疗前平均33.97ng/ml降低至化疗后22.11ng/ml,明显与患者化疗的反应率相关(P<0.001)。结论晚期乳癌者在治疗过程中血清Her-2/neu浓度的变化可作为判断化疗疗效的指标。

关键词: 血清Her-2/neu

Abstract: Objective To investigate the relationship between efficacy of chemotherapy and serum Her-2/neu concentration in patients with advanced breast cancer,and to analyze its clinical significance.Methods Serum Her-2/neu concentration before and after chemotherapy collected from 66 cases of advanced breast cancer were detected by ELISA and the results were compared with Her-2/neu expression in tissues.The correlation,the efficacy of chemotherapy and time to progress(TTP) were analyzed. Results Serum Her-2/neu concentration was consistent with the expression of Her-2/neu in tumor tissues of patient with advanced breast cancer(P<0.001).The level of Her-2/neu before chemotherapy had no relation to efficacy of chemotherapy (P>0.05).Mean serum Her-2/neu concentration decreased from 33.97ng/ml to 22.11ng/ml after treatment in patient who was effective to chemotherapy,indicating the correlation to response rate of chemotherapy(P<0.001).Conclusion The changes of serum Her-2/neu concentration are significantly associated with efficacy of chemotherapy.Her-2/neu may be used as an indicator in the course of treatment Elevated serum Her-2/neu concentration before chemotherapy was correlated to shorter overall survival.

Key words: Serum Her-2/neu, Advanced breast cancer, Efficacy of chemotherapy

宋向群;周建红;于起涛;曾爱屏;周达;何剑波;. 晚期乳腺癌患者血清Her-2/neu浓度与化疗疗效的关系[J]. 中国癌症防治杂志, 2009, 1(01): 30-32.

SONG Xiang-qun,ZHOU Jian-hong,YU Qitao.et al.. Serum concentration of Her-2/neu in patients with advanced breast cancer and its relationship with efficacy of chemotherapy[J]. Chinese Journal of Oncology Prevention and Treatment, 2009, 1(01): 30-32.

参考文献

1 Carney WP,Neumann R,Lipton A,et al.Potential clinical utility of serum Her-2/ neu oncoprotein concentrations in patients with breast cancer[J].Clin Chem, 2003,49(10):1579-98. 2 Souder C,Leitzel K,Ali SM,et al.Serum epidermal growth factor receptor/Her-2 predicts poor survival in patients with metastatic breast cancer[J].Cancer,2006, 107(10):2337-45. 3 Colomer R,Montero S,Lluch A,et al.Circulating Her-2 extracellular domain and resistance to chemotherapy in advanced breast cancer[J].Clin Cancer Res,2000,6 (6):2356-62. 4 Colomer R,Uombart CA,Lloveras B,et al.High circulating Her-2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor -positive metastatic breast cancer;a confirmatory prospective study[J],Cancer, 2007,110(10):2178-85. 5袁芃,徐兵河,张春,等.乳腺癌患者血清Her-2/neu水平及相关性研究[J].中华肿瘤杂志,2003,25(6):573-574. 6 Volkmar M,Isabell W,Hans J,et al.Prognostic and predictive impact of the Her-2/ neu extracellular domain(ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer[J],Breast Cancer Research and Treatment,2004,86: 9-18. 7 Cook GB,Neaman IE,Goldblatt JL,et al.Clinical utility of serum Her-2/neu testing on the Bayer immunol automated system in breast cancer[J].Anticancer Res, 2001,2t(2B):1465-70. 8 Jeffrey S,Ross,Jonathan A.Targeted therapy in breast cancer[J].Molecular & Cellular Proteomics,2004,3(4):379-398. 9 Fehm T,Solomayer E,Duerr-Stoerzer S,et al.Determination of Her-2 status using both serum Her-2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was Her-2 negative or of unknown Her-2 status[J] .Breast Cancer Res,2007,9(5):R74. 10 Classen S,Kopp R,Possinger K,et al.Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second line hormone or chemotherapy[J].Tumor Biol,2002,23:70-75.